Magnetic resonance imaging (MRI) techniques such as magnetization transfer imaging and magnetic resonance spectroscopy (MRS) may reveal otherwise undetectable tissue damage in multiple sclerosis (MS) and can serve to explain more severe disability than expected from conventional MRI. That an inverse situation may exist where non-conventional quantitative MRI and MRS metrics would indicate less abnormality than expected from T2 lesion load to explain preserved clinical functioning was hypothesized. Quantitative MRI and MRS were obtained in 13 consecutive patients with clinically benign MS (BMS; mean age 44 ± 9 years) despite large T 2 lesion load and in 15 patients with secondary progressive MS (SPMS; mean age 47 ± 6 years) matched for disease duration. The magnetization transfer ratio (MTR), magnetization transfer rate (kfor), brain parenchymal fraction (BPF) and brain metabolite concentrations from proton MRS were determined. BMS patients were significantly less disabled than their SPMS counterparts (mean expanded disability status score: 2.1 ± 1.1 versus 6.2 ± 1.1; P < 0.001) and had an even somewhat higher mean T2 lesion load (41.2 ± 27.1 versus 27.9 ± 24.8 cm3; P = 0.19). Normal appearing brain tissue histogram metrics for MTR and kfor, mean MTR and kfor of MS lesions and mean BPF were similar in BMS and SPMS patients. Levels of N-acetyl-aspartate, choline and myoinositol were comparable between groups. This study thus failed to explain the preservation of function in our BMS patients with large T2 lesion load by a higher morphologic or metabolic integrity of the brain parenchyma. Functional compensation must come from other mechanisms such as brain plasticity. Multiple Sclerosis 2008; 14: 205—211. http://msj.sagepub.com
Miller D., Grossman R., Reingold S., McFarland H.The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain1998; 121: 3—24.
2.
Filippi M., Rocca M., Arnold D., Bakshi R., Barkhof F., De Stefano N. et al. EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol2006; 13(4): 313—25.
3.
Barkhof F.MRI in multiple sclerosis: correlation with expanded disability scale (EDSS) . Mult Scler1999; 5: 283—6.
Bo L., Geurts J., Mork S., Van der Valk P.Grey matter pathology in multiple sclerosis. Acta Neurol Scand Suppl2006; 183: 48—50.
6.
Miller D., Thompson A., Filippi M.Magnetic resonance studies of abnormalities in the normal appearing white matter and gray matter in multiple sclerosis. J Neurol2003; 250: 1407—19.
7.
Filippi M., Rocca MGC.The use of quantitative magnetic-resonance-based technique to monitor the evolution of multiple sclerosis. Lancet Neurol2003; 2(6): 337—46.
8.
Traboulsee A. , Dehmeshki J., Peters K., Griffin C., Brex P., Silver N. et al. Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. Mult Scler2003; 9(6): 566—73.
9.
Anderson V., Fox N., Miller D.Magnetic resonance imaging measures of brain atrophy in multiple sclerosis . J Magn Reson Imaging2006; 23(5): 605—18.
10.
Falini A., Calabrese M., Filippi M., Origgi D., Lipari S., Colombo B. et al. Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability . Am J Neuroradiol1998; 19: 223—9.
11.
Mainero C., De Stefano N., Iannucci G., Sormani M., Guidi L., Federico A. et al. Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology2001; 56(10): 1331—4.
12.
Ramsaransing G., De Keyser J.Benign course in multiple sclerosis: a review . Acta Neurol Scand2006; 113: 359—69.
13.
Perini P., Tagliaferri C., Belloni M., Biasi G., Gallo P.The HLA-DR13 haplotype is associated with “benign” multiple sclerosis in northeast Italy. Neurology2001 ; 57: 158—9.
14.
Lublin F., Reingold S.Defining the clinical course of multiple sclerosis: results of an international survey. Neurology1996; 46: 907—11.
15.
Kurtzke J.Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983; 33: 1444—52.
16.
Plummer D.DispImage: a display and analysis tool for medical images. Revista di Neuroradiologica1992; 5: 489—95.
17.
Ropele S., Stollberger R., Hartung H., Fazekas F.Estimation of magnetization transfer rates from PACE experiments with pulsed RF saturation. J Magn Res Imag2000 ; 12: 749—56.
18.
Ropele S., Bammer R., Stollberger R., Fazekas F.T1 maps from shifted spin echoes and stimulated echoes. Magn Reson Med2001; 46: 1242—5.
19.
Schmierer K. , Scaravilli F., Altmann D., Barker G., Miller D.Magnetization transfer ratio and myelin in post-mortem multiple sclerosis brain. Ann Neurol2004; 56: 407—15.
20.
Fazekas F., Ropele S., Enzinger C., Seifert T., Strasser-Fuchs S.Quantitative magnetization transfer imaging of pre-lesional white-matter changes in multiple sclerosis. Mult Scler2002; 8: 479—84.
21.
Smith S., de Stefano N., Jenkinson M., Matthews P.Normalized accurate measurements of longitudinal brain change. J Comput Assist Tomogr2001; 25(3): 466—75.
22.
Enzinger C. , Ropele S., Strasser-Fuchs S., Kapeller P., Schmidt H., Poltrum B. et al. Lower levels of N-acetylaspartate in multiple sclerosis patients with the apolipoprotein E ε4 allele. Arch Neurol2003; 60: 65—70.
23.
Kapeller P. , Ropele S., Enzinger C., Lahousen T., Strasser-Fuchs S., Schmidt R. et al. Discrimination of white matter lesions and multiple sclerosis plaques by short echo quantitative 1H-magnetic resonance spectroscopy. J Neurol2005; 252(10): 1229—34.
24.
Provencher S.Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Res Med1993; 30: 672—9.
25.
Filippi M., Falini A., Arnold D., Fazekas F., Gonen O., Simon J. et al. Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: consensus report of the white matter study group . J Magn Res Imag2005; 21(6): 669—75.
26.
Filippi M.Magnetization transfer MRI in multiple sclerosis and other central nervous system disorders. Eur J Neurol2003 ; 10(1): 3—10.
27.
Bakshi R., Dandamudi V., Neema M., De C., Bermel R.Measurement of brain and spinal cord atrophy by magnetic resonance imaging as a tool to monitor multiple sclerosis. J Neuroimag2005; 15(Suppl 4): 30S—45S.
28.
Tartaglia M. , Arnold D.The role of MRS and fMRI in multiple sclerosis . Adv Neurol2006; 98: 185—202.
29.
Li D., Zhao G., Paty D., and the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group.Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results . Neurology2001; 56(11): 1505—13.
30.
Fazekas F., Sorensen P., Filippi M., Ropele S., Lin X., Koelmel H. et al. MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Mult Scler2005; 11(4): 433—40.
31.
Miller D., Molyneux P., Barker G., MacManus D., Moseley I., Wagner K. et al. Effect of interferon-beta 1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicentre, randomized, double-blind, placebo-controlled trial. Ann Neurol1999; 46: 850—9.
32.
De Stefano N., Battaglini M., Stromillo M., Zipoli V., Bartolozzi M., Guidi L. et al. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain2006; 129: 2008—16.
33.
Koopmans R. , Li D., Grochowsky E., Cutler P., Paty D.Benign versus chronic progressive multiple sclerosis: magnetic resonance imaging features. Ann Neurol1989; 25: 74—81.
34.
Filippi M., Campi A., Mammi S., Martinelli V., Locatelli T., Scotti G. et al. Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry1995; 58(1): 31—7.
35.
De Stefano N., Narayanan S., Francis S., Smith S., Mortilla M., Tartaglia M. et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability . Arch Neurol2002; 59(10): 1565—71.
36.
Filippi M., Bozzali M., Rovaris M., Gonen O., Kesavadas C., Ghezzi A., et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain2003; 126(Pt 2): 433—7.
37.
De Stefano N., Narayanan S., Francis G., Arnaoutelis R., Tartaglia M., Antel J. et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol2001; 58: 65—70.
38.
Rocca M., Colombo B., Falini A., Ghezzi A., Martinelli V., Scotti G. et al. Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol2005; 4(10): 618—28.
39.
Rao S., Leo G., Haughton V., Aubin-Faubert S., Bernardin L.Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology1989 ; 39: 161—6.
40.
Lin X., Blumhardt L., Constantinescu C.The relationship of brain and cervical cord volume to disability in clinical subtypes of multiple sclerosis: a three-dimensional MRI study. Acta Neurol Scand2003; 108(6): 401—6.
41.
Bieniek M., Altmann D., Davies G., Ingle G., Rashid W., Sastre-Garriga J. et al. Cord atrophy separates early primary progressive and relapsing multiple sclerosis. J Neurol Neurosurg Psychiatry2006; 77(9): 1036—9.
42.
Brass S., Narayanan S., Antel J., Lapierre Y., Collins L., Arnold D.Axonal damage in multiple sclerosis patients with high versus low expanded disability status scale score. Can J Neurol Sci2004; 31(2): 225—228.
